A month has gone by since the last earnings report for Xenon Pharmaceuticals (XENE). Shares have added about 4.2% in that time frame, outperforming the S&P 500.But investors have to be wondering, will ...

- Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 - Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED ...